ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025
Surgery-based multimodal therapy outperforms chemoradiotherapy alone in HPV-negative advanced HSCC: superior outcomes for T3/N2-3 hypopharyngeal squamous cell carcinoma.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
objectiveTo explore whether the Human Papillomavirus (HPV) status plays a role in the selection of treatments for hypopharyngeal squamous cell carcinoma (HSCC), we compared the survival outcomes of patients with different HPV statuses who underwent surgery combined with chemoradiotherapy and chemoradiotherapy alone.
methodsPatient's data were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), multivariate Cox regression analysis, and Kaplan‒Meier analysis were conducted.
results591 patients were obtained from the SEER database. The study revealed that HPV-positive HSCC patients had better cancer specific survival (CSS) (P = 0.009) and overall survival (OS) (P < 0.001). These findings were also supported by Multivariate Cox regression analysis. Kaplan‒Meier analysis revealed that surgery significantly improved CSS (P = 0.023) and OS (P = 0.004) in HPV-negative HSCC patients. However, for HPV-positive patients, there was no significant improvement in CSS (P = 0.565) or OS (P = 0.863). Similar results were obtained after PSM. We further analyzed that among HPV-negative patients with stage T3 disease, surgery significantly improved the 5-year OS rate (12.17% vs. 62.06%; P = 0.002) and CSS rate (25.90% vs. 68.15%; P = 0.019). For stage N2-3 HPV-negative HSCC patients, the 5-year OS and CSS of the surgery group and no surgery group were 62.31% vs. 29.76% (P = 0.011) and 65.59% vs. 44.39% (P = 0.104), respectively. However, for HPV-positive patients with different T stages and N stages, there was no significant survival difference.
conclusionsSurgery combined with chemoradiotherapy is more suitable for HPV-negative patients with stage T3 and stage N2-3 disease.
Indexed as
Identifiers
41136576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.